CLL Tracker Results (2010)

NOTE: All results are numerical numbers unless otherwise stated.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The charts above and below should be viewed together. The median age at diagnosis for Female group = 61.5 years and for Male group = 60.5 years. The distribution of age at diagnosis for the female group (47 and 78 years) and the male group (42 and 79 years).

 

The above chart measures the time from the completion of the first treatment to the start of the second treatment for Fludarabine and Cyclophosphamide (FC). 8 patients were treated with FC and 5 had relapsed needing further treatment. The median time between treatments was 33 months.

Patient 4 failed treatment due to treatment complications.

The below chart measures the time from the completion of the first treatment to the start of the second treatment for Fludarabine, Cyclophosphamide and Rituxan (RFC). 22 patients were treated with RFC and only 6 had relapsed needing further treatment. The median time between treatments was 26.6 months.

The interesting point is that all but one of the 6 patients treated with Fludarabine and Cyclophosphamide had received re-treatment, but for RFC 14 remained untreated.

Patient's 1 and 2 both failed treatment due to treatment complications.